538 related articles for article (PubMed ID: 25868121)
1. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
2. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
4. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2014 Apr; 34(2):256-60. PubMed ID: 24525658
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Hendset M; Molden E; Knape M; Hermann M
Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Rafaniello C; Sessa M; Bernardi FF; Pozzi M; Cheli S; Cattaneo D; Baldelli S; Molteni M; Bernardini R; Rossi F; Clementi E; Bravaccio C; Radice S; Capuano A
Pharmacogenomics J; 2018 May; 18(3):422-430. PubMed ID: 28719598
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
9. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.
Kiss Á; Menus Á; Tóth K; Déri M; Sirok D; Gabri E; Belic A; Csukly G; Bitter I; Monostory K
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):71-82. PubMed ID: 30604050
[TBL] [Abstract][Full Text] [Related]
10. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
12. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; De Vries R; Kaneko S
J Clin Pharmacol; 2002 Oct; 42(10):1083-8. PubMed ID: 12362921
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
[TBL] [Abstract][Full Text] [Related]
15. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.
Du J; Zhang A; Wang L; Xuan J; Yu L; Che R; Li X; Gu N; Lin Z; Feng G; Xing Q; He L
J Psychopharmacol; 2010 Jul; 24(7):1115-20. PubMed ID: 19395426
[TBL] [Abstract][Full Text] [Related]
16. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
17. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
[TBL] [Abstract][Full Text] [Related]
19. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
[TBL] [Abstract][Full Text] [Related]
20. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
